This content is only available for ASCRS Members
ASCRS Membership offers access to 1,000+ educational resources on demand.
Learn More About ASCRS Membership
A documented OCP case started Rituximab to control the disease activity. The inflammation subsided 6 months after taking the 1st dose. After counseling the patient and his son, 2 areas-3 clock hours- limbal stem cells from his son were taken. Periotomy was done to the patient left eye with removal of fibrous tissues over the cornea. Stem cells were sutured over one layer of amniotic membrane.
